ALNY
Price
$400.59
Change
-$0.10 (-0.02%)
Updated
Dec 26 closing price
Capitalization
52.92B
46 days until earnings call
Intraday BUY SELL Signals
BBIO
Price
$75.80
Change
-$0.73 (-0.95%)
Updated
Dec 26 closing price
Capitalization
14.61B
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALNY vs BBIO

Header iconALNY vs BBIO Comparison
Open Charts ALNY vs BBIOBanner chart's image
Alnylam Pharmaceuticals
Price$400.59
Change-$0.10 (-0.02%)
Volume$401.46K
Capitalization52.92B
BridgeBio Pharma
Price$75.80
Change-$0.73 (-0.95%)
Volume$1.09M
Capitalization14.61B
ALNY vs BBIO Comparison Chart in %
View a ticker or compare two or three
VS
ALNY vs. BBIO commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and BBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (ALNY: $400.59 vs. BBIO: $75.80)
Brand notoriety: ALNY and BBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 30% vs. BBIO: 46%
Market capitalization -- ALNY: $52.92B vs. BBIO: $14.61B
ALNY [@Biotechnology] is valued at $52.92B. BBIO’s [@Biotechnology] market capitalization is $14.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 2 FA rating(s) are green whileBBIO’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 2 green, 3 red.
  • BBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, ALNY is a better buy in the long-term than BBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while BBIO’s TA Score has 3 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 4 bearish.
  • BBIO’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than BBIO.

Price Growth

ALNY (@Biotechnology) experienced а +0.09% price change this week, while BBIO (@Biotechnology) price change was -0.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

ALNY is expected to report earnings on Feb 12, 2026.

BBIO is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($52.9B) has a higher market cap than BBIO($14.6B). BBIO YTD gains are higher at: 176.239 vs. ALNY (70.239). ALNY has higher annual earnings (EBITDA): 187M vs. BBIO (-640.87M). ALNY has more cash in the bank: 2.73B vs. BBIO (646M). ALNY has less debt than BBIO: ALNY (1.31B) vs BBIO (1.86B). ALNY has higher revenues than BBIO: ALNY (3.21B) vs BBIO (354M).
ALNYBBIOALNY / BBIO
Capitalization52.9B14.6B362%
EBITDA187M-640.87M-29%
Gain YTD70.239176.23940%
P/E Ratio1335.30N/A-
Revenue3.21B354M907%
Total Cash2.73B646M422%
Total Debt1.31B1.86B70%
FUNDAMENTALS RATINGS
ALNY vs BBIO: Fundamental Ratings
ALNY
BBIO
OUTLOOK RATING
1..100
8928
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
1373
SMR RATING
1..100
29100
PRICE GROWTH RATING
1..100
5036
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (3) in the null industry is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that BBIO’s stock grew significantly faster than ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (13) in the Biotechnology industry is somewhat better than the same rating for BBIO (73) in the null industry. This means that ALNY’s stock grew somewhat faster than BBIO’s over the last 12 months.

ALNY's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for BBIO (100) in the null industry. This means that ALNY’s stock grew significantly faster than BBIO’s over the last 12 months.

BBIO's Price Growth Rating (36) in the null industry is in the same range as ALNY (50) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for BBIO (100) in the null industry. This means that ALNY’s stock grew somewhat faster than BBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYBBIO
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
59%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
67%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
64%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signal:
Gain/Loss:
BBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IGEB45.770.02
+0.04%
iShares Investment Grade Systmtc Bd ETF
FUND8.73N/A
N/A
Sprott Focus Trust
UX30.28-0.02
-0.06%
Roundhill Uranium ETF
CFIT25.24-0.04
-0.18%
Cambria Fixed Income Trend ETF
PSCE42.75-0.22
-0.51%
Invesco S&P SmallCap Energy ETF

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
-0.02%
ARGX - ALNY
52%
Loosely correlated
-0.59%
SGMO - ALNY
42%
Loosely correlated
-4.49%
IONS - ALNY
37%
Loosely correlated
-0.89%
ALLO - ALNY
37%
Loosely correlated
-1.43%
BBIO - ALNY
36%
Loosely correlated
-0.95%
More

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-0.95%
AXON - BBIO
44%
Loosely correlated
-1.24%
ARRY - BBIO
43%
Loosely correlated
+0.39%
PMN - BBIO
43%
Loosely correlated
-7.38%
XENE - BBIO
42%
Loosely correlated
-0.38%
AVBP - BBIO
42%
Loosely correlated
-1.44%
More